

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	NUNC PRO TUNC ASSIGNMENT
EFFECTIVE DATE:	07/31/2000

CONVEYING PARTY DATA

Name	Execution Date
Robert E. Fischell	07/24/2009
David R. Fischell	07/24/2009
Adrian R.M. Upton	07/30/2009

RECEIVING PARTY DATA

Name:	NeuroPace, Inc.
Street Address:	1375 Shorebird Way
City:	Mountain View
State/Country:	CALIFORNIA
Postal Code:	94043

PROPERTY NUMBERS Total: 1

Property Type	Number
Patent Number:	6402678

CORRESPONDENCE DATA

Fax Number: (650)237-2701
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
 Phone: 6502372743
 Email: pmaher@neuropace.com
 Correspondent Name: Pamela Maher
 Address Line 1: 1375 Shorebird Way
 Address Line 4: Mountain View, CALIFORNIA 94043

ATTORNEY DOCKET NUMBER:	N09-00
NAME OF SUBMITTER:	Pamela G. Maher

Total Attachments: 7

500927344

**PATENT
 REEL: 023044 FRAME: 0146**

CH \$40.00 6402678

source=NuncProTunc6402678RobertF#page1.tif
source=NuncProTunc6402678RobertF#page2.tif
source=NuncProTunc6402678DavidF#page1.tif
source=NuncProTunc6402678DavidF#page2.tif
source=NuncProTunc6402678Upton#page1.tif
source=NuncProTunc6402678Upton#page2.tif
source=NuncProTunc6402678Upton#page3.tif

NUNC PRO TUNC ASSIGNMENT (PATENT)

Robert E. FISCHHELL, David R. FISCHHELL, and Adrian R.M. UPTON (hereinafter "Assignors"), residing at 14600 Vibrunum Drive, Dayton, Maryland, US 21036, 71 Riverlawn Drive, Fair Haven, New Jersey UA 07704, and 78 Highland Park Drive, Dundas, Ontario, Canada respectively, witnesseth:


This *NUNC PRO TUNC ASSIGNMENT* is to confirm that NeuroPace, Inc., has owned the entire right, title and interest in and to U.S. Patent No. 6,402,678 by reason of an obligation to assign said right, title and interest on the part of the inventors named on U.S. Patent No. 6,402,678 patent, namely, Robert E. Fischell, David R. Fischell, and Adrian R.M. Upton, as of the date the application on which the patent issued was filed and as of the date the subject matter disclosed in the patent was invented, whichever date is earlier.

U.S. Patent No. 6,402,678 for "Means and Methods for the Treatment of Migraine Headaches" issued June 11, 2002 on an application filed July 31, 2000 and corresponding to U.S. Patent Application Serial No. 09/629,210. An international application corresponding to Patent Cooperation Treaty Application No. PCT/US01/23598 was filed asserting priority to U.S. Serial No. 09/629,210 on July 31, 2001 which resulted in granted European Patent EP 1 307 260 with parts in Great Britain, France and Germany (DE 60124259) and still pending Canadian Patent Application Publication No. 2423840.

NOW, THEREFORE, for valuable, good and sufficient consideration, the receipt of which is hereby acknowledged, Assignors hereby assign *nunc pro tunc*, effective as of July 31, 2000 all rights, title and interest in and to U.S. Patent No. 6,402,678, including but not limited to the right to sue for past infringement and all rights, title and interest in and to the above-identified foreign patents and application that assert priority to the application on which U.S. Patent No. 6,402,678 issued, the same to be held and enjoyed by NeuroPace, Inc. for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which the U.S. patent or any foreign patent has been or may be granted, as fully and entirely as the same would have been held and enjoyed by the Assignors, had this sale and assignment not been made.

AND, for the same consideration, Assignors hereby covenant and agree to and with NeuroPace, Inc. and its successors, legal representatives and assigns, that Assignors will, whenever counsel of NeuroPace, Inc., or the counsel of its successors, legal representatives and assigns, shall advise that any proceeding in connection with a patent for said inventions in any country, including interference proceedings, is lawful and desirable, or that any division, continuation, or continuation-in-part of any application for patent or any reissue or extension of any patent, to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and


defense of the patent(s) for said inventions, without charge to NeuroPace, Inc, its successors, legal representatives and assigns, but at the cost and expense of NeuroPace, Inc. or, as applicable, its successors, legal representatives and assigns.

07/24/09	
Date	Robert E. Fischell
Date	David R. Fischell
Date	Adrian R. M. Upton

ACKNOWLEDGED:

By: Frank M. Fischer
Frank M. Fischer
President and Chief Executive Officer
NeuroPace, Inc.

Date: 7/31, 2009

Notarized Robert E. Fischell Signature

Notary

NUNC PRO TUNC ASSIGNMENT (PATENT)

Robert E. FISCHELL, David R. FISCHELL, and Adrian R.M. UPTON (hereinafter "Assignors"), residing at 14600 Vibrunum Drive, Dayton, Maryland, US 21036, 71 Riverlawn Drive, Fair Haven, New Jersey UA 07704, and 78 Highland Park Drive, Dundas, Ontario, Canada respectively, witnesseth:


This *NUNC PRO TUNC ASSIGNMENT* is to confirm that NeuroPace, Inc., has owned the entire right, title and interest in and to U.S. Patent No. 6,402,678 by reason of an obligation to assign said right, title and interest on the part of the inventors named on U.S. Patent No. 6,402,678 patent, namely, Robert E. Fischell, David R. Fischell, and Adrian R.M. Upton, as of the date the application on which the patent issued was filed and as of the date the subject matter disclosed in the patent was invented, whichever date is earlier.

U.S. Patent No. 6,402,678 for "Means and Methods for the Treatment of Migraine Headaches" issued June 11, 2002 on an application filed July 31, 2000 and corresponding to U.S. Patent Application Serial No. 09/629,210. An international application corresponding to Patent Cooperation Treaty Application No. PCT/US01/23598 was filed asserting priority to U.S. Serial No. 09/629,210 on July 31, 2001 which resulted in granted European Patent EP 1 307 260 with parts in Great Britain, France and Germany (DE 60124259) and still pending Canadian Patent Application Publication No. 2423840.

NOW, THEREFORE, for valuable, good and sufficient consideration, the receipt of which is hereby acknowledged, Assignors hereby assign *nunc pro tunc*, effective as of July 31, 2000 all rights, title and interest in and to U.S. Patent No. 6,402,678, including but not limited to the right to sue for past infringement and all rights, title and interest in and to the above-identified foreign patents and application that assert priority to the application on which U.S. Patent No. 6,402,678 issued, the same to be held and enjoyed by NeuroPace, Inc. for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which the U.S. patent or any foreign patent has been or may be granted, as fully and entirely as the same would have been held and enjoyed by the Assignors, had this sale and assignment not been made.

AND, for the same consideration, Assignors hereby covenant and agree to and with NeuroPace, Inc. and its successors, legal representatives and assigns, that Assignors will, whenever counsel of NeuroPace, Inc., or the counsel of its successors, legal representatives and assigns, shall advise that any proceeding in connection with a patent for said inventions in any country, including interference proceedings, is lawful and desirable, or that any division, continuation, or continuation-in-part of any application for patent or any reissue or extension of any patent, to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and

defense of the patent(s) for said inventions, without charge to NeuroPace, Inc, its successors, legal representatives and assigns, but at the cost and expense of NeuroPace, Inc. or, as applicable, its successors, legal representatives and assigns.

Date	Robert E. Fischell
7/24/09	
Date	David R. Fischell
Date	Adrian R. M. Upton

ACKNOWLEDGED:

By: Frank M. Fischer
Frank M. Fischer
President and Chief Executive Officer
NeuroPace, Inc.

Date: 7/31, 2009

***NUNC PRO TUNC* ASSIGNMENT (PATENT)**

Robert E. FISCHHELL, David R. FISCHHELL, and Adrian R.M. UPTON (hereinafter "Assignors"), residing at 14600 Vibrunum Drive, Dayton, Maryland, US 21036, 71 Riverlawn Drive, Fair Haven, New Jersey UA 07704, and 78 Highland Park Drive, Dundas, Ontario, Canada respectively, witnesseth:


This *NUNC PRO TUNC* ASSIGNMENT is to confirm that NeuroPace, Inc., has owned the entire right, title and interest in and to U.S. Patent No. 6,402,678 by reason of an obligation to assign said right, title and interest on the part of the inventors named on U.S. Patent No. 6,402,678 patent, namely, Robert E. Fischell, David R. Fischell, and Adrian R.M. Upton, as of the date the application on which the patent issued was filed and as of the date the subject matter disclosed in the patent was invented, whichever date is earlier.

U.S. Patent No. 6,402,678 for "Means and Methods for the Treatment of Migraine Headaches" issued June 11, 2002 on an application filed July 31, 2000 and corresponding to U.S. Patent Application Serial No. 09/629,210. An international application corresponding to Patent Cooperation Treaty Application No. PCT/US01/23598 was filed asserting priority to U.S. Serial No. 09/629,210 on July 31, 2001 which resulted in granted European Patent EP 1 307 260 with parts in Great Britain, France and Germany (DE 60124259) and still pending Canadian Patent Application Publication No. 2423840.

NOW, THEREFORE, for valuable, good and sufficient consideration, the receipt of which is hereby acknowledged, Assignors hereby assign *nunc pro tunc*, effective as of July 31, 2000 all rights, title and interest in and to U.S. Patent No. 6,402,678, including but not limited to the right to sue for past infringement and all rights, title and interest in and to the above-identified foreign patents and application that assert priority to the application on which U.S. Patent No. 6,402,678 issued, the same to be held and enjoyed by NeuroPace, Inc. for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which the U.S. patent or any foreign patent has been or may be granted, as fully and entirely as the same would have been held and enjoyed by the Assignors, had this sale and assignment not been made.

AND, for the same consideration, Assignors hereby covenant and agree to and with NeuroPace, Inc. and its successors, legal representatives and assigns, that Assignors will, whenever counsel of NeuroPace, Inc., or the counsel of its successors, legal representatives and assigns, shall advise that any proceeding in connection with a patent for said inventions in any country, including interference proceedings, is lawful and desirable, or that any division, continuation, or continuation-in-part of any application for patent or any reissue or extension of any patent, to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and

defense of the patent(s) for said inventions, without charge to NeuroPace, Inc, its successors, legal representatives and assigns, but at the cost and expense of NeuroPace, Inc. or, as applicable, its successors, legal representatives and assigns.

Date	Robert E. Fischell
Date	David R. Fischell
	
Date	Adrian R. M. Upton

ACKNOWLEDGED:

By: Frank M. Fischer
Frank M. Fischer
President and Chief Executive Officer
NeuroPace, Inc.

Date: Aug 3, 2009


NOTARIAL CERTIFICATE

CANADA)
PROVINCE OF ONTARIO)
)

On this day, before me, **Michele Ballagh**, of the City of Hamilton, in the Province of Ontario, Barrister & Solicitor, a Notary Public by royal authority duly appointed, personally _____ appeared

ADRIAN UPTON personally known to me or proved to me upon satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the attached instrument and acknowledged to me that s/he/they executed same in his/her/their authorized capacity and that by his/her/their signature on the instrument did so execute the instrument.

IN TESTIMONY WHEREOF I have hereunto subscribed my name and affixed my seal of office at the City of Hamilton, in the Province of Ontario, this 30th day of July, 2009.



Michele Ballagh Seal
A Notary Public in and for the Province of Ontario